Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability

Mol Pharm. 2018 Feb 5;15(2):394-402. doi: 10.1021/acs.molpharmaceut.7b00761. Epub 2017 Dec 21.

Abstract

Neuropilin-1 (NRP1), which functions as a coreceptor for vascular endothelial growth factor (VEGF) and is implicated in vascular permeability and tumorigenesis, has been targeted by peptides that specifically bind to the VEGF-binding region on NRP1. Like natural VEGF ligands, all known peptides with NRP1-binding activity bind only through a carboxy (C)-terminal R/K-x-x-R/K sequence motif (x stands for any amino acids); this strict requirement is called the C-end rule (CendR). Here, we report immunoglobulin Fc-fused NRP1-specific peptides deviating from CendR. We screened a yeast surface-displayed Fc-fused non-CendR peptide library against NRP1 and isolated Fc-V12, wherein V12 peptide comprising 12 amino acids has a PPRV sequence at its C-terminal end. Although Fc-V12 lacked the CendR motif, it showed selective binding to the VEGF-binding region of NRP1 and triggered cellular internalization of NRP1, which resulted in enhanced extravasation into tumor tissues and tumor tissue penetration of the Fc-fused peptide along with the coinjected chemical drug in tumor-bearing mice. Through a saturation mutagenesis study, we identified that the Val residue at the C-terminus of Fc-V12 is crucial for NRP1 binding. We further improved NRP1 affinity of Fc-V12 (KD = ∼761 nM) through directed evolution of the upstream sequence of PPRV to obtain Fc-V12-33 (KD = ∼17.4 nM), which exhibited enhanced NRP1-mediated vascular permeability as compared with Fc-V12. Our results provide functional Fc-fused non-CendR peptides, which bind to the VEGF-binding region of NRP1 and enhance vascular permeability, expanding the sequence space of NRP1-targeting peptides.

Keywords: C-end rule; neuropilin-1; peptide engineering; vascular permeability; yeast surface display.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Capillary Permeability / drug effects*
  • Carcinogenesis / drug effects
  • Cell Line, Tumor
  • Female
  • Humans
  • Immunoglobulin Fc Fragments / genetics
  • Immunoglobulin Fc Fragments / isolation & purification
  • Immunoglobulin Fc Fragments / pharmacology*
  • Immunoglobulin Fc Fragments / therapeutic use
  • Ligands
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Mutagenesis
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neuropilin-1 / genetics
  • Neuropilin-1 / isolation & purification
  • Neuropilin-1 / metabolism*
  • Peptides / genetics
  • Peptides / isolation & purification
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Protein Binding
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / isolation & purification
  • Recombinant Fusion Proteins / pharmacology*
  • Recombinant Fusion Proteins / therapeutic use
  • Vascular Endothelial Growth Factor A / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Immunoglobulin Fc Fragments
  • Ligands
  • NRP1 protein, human
  • Peptides
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Neuropilin-1